1. Morgan DO. Principles of CDK regulation. Nature 374:131–1341995.
2. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211–2191995.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–7071993.
4. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–8161993.
5. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701–7041993.
6. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 8:59–661994.
7. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–8251993.
8. Lee MH, Reynisdottir I, Massague J. Cloning of p57KP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9:639–6491995.
9. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371:257–2611994.
10. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet 8:15–211994.
11. Lee YY, Kang SH, Seo JY, Jung CW, Lee KU, Choe KJ, Kim BK, Kim NK, Koeffler HP, Bang YJ. Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. Cancer 80:1889–18961997.
13. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79:2067–20721997.
15. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227–2301997.
16. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231–2341997.
17. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381–33851997.
20. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adeno- carcinoma. Cancer Res 58:542–5481998.
21. Holistein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551–35551994.
23. Kim JH, Uhm HD, Gong SJ, Shin DH, Choi JH, Lee HR, Noh SH, Kim BS, Cho JY, Rha SY, Yoo NC, Chung HC, Roh JK, Min JS, Lee KS, Kim BS. Relationship between p53 overexpression and gastric cancer progression. Oncology 54:166–1701997.
25. Maestro R, Gloghini A, Doglioni C, Piccinin S, Vukosavljevic T, Gasparotto D, Carbone A, Boiocchi M. Human non-Hodgkin’s lymphomas overexpress a wild-type form of p53 which is a functional transcriptional activator of the cyclin-dependent kinase inhibitor p21. Blood 89:2523–25281997.
26. Sheikh MS, Rochefort H, Garcia M. Overexpression of p21 WAF1/IP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene 11:1899–19051995.
27. American Joint Committee on Cancer Stomach cancer. Manual for staging cancer. ed 5. revised. Philadelphia: Lippincott-Raven, 71–761997.
28. Reed JA, Manahan LJ, Park CS, Brigati DJ. Complete one-hour immunohistochemistry based on capillary action. Biotechniques 13:434–4431992.
29. Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K. Growth pattern and expressions of cell cycle regulator proteins p53 and p21WAFI/CIP1 in early gastric carcinoma. Cancer 92:1828–18352001.
30. Ikeguchi M, Saito H, Katano K, Tsujitani S, Maeta M, Kaibara N. Expression of p53 and p21 are independent prognostic factors in patients with serosal invasion by gastric carcinoma. Dig Dis Sci 43:964–9701998.
31. Chan AOO, Luk JM, Hui WM, Lam SK. Molecular biology of gastric carcinoma: From laboratory to bedside. J Gastroenterol Hepatol 14:1150–11601999.
33. Sherr CJ. Cancer cell cycles. Science 274:1672–16771996.
34. Kaye PV, Radebold K, Isaacs S, Dent DM. Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol 26:39–432000.
35. Muller W, Noguchi T, Wirtz HC, Hommel G, Gabbert HE. Expression of cell-cycle regulatory proteins cyclin D1, cyclin E and their inhibitor p21 WAF1/CIP1 in gastric cancer. J Pathol 189:186–1931999.
36. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54:3391–33951994.
37. Xiangming C, Hokita S, Natsugoe S, Tanabe G, Baba M, Takao S, Kuroshima K, Aikou T. p21 expression is a prognostic factor in patients with p53-negative gastric cancer. Cancer Lett 148:181–1882000.